Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer ☆
Titel:
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer ☆
Auteur:
Bardia, A. Tolaney, S.M. Punie, K. Loirat, D. Oliveira, M. Kalinsky, K. Zelnak, A. Aftimos, P. Dalenc, F. Sardesai, S. Hamilton, E. Sharma, P. Recalde, S. Gil, E.C. Traina, T. O’Shaughnessy, J. Cortes, J. Tsai, M. Vahdat, L. Diéras, V. Carey, L.A. Rugo, H.S. Goldenberg, D.M. Hong, Q. Olivo, M. Itri, L.M. Hurvitz, S.A.